Sirona Biochem Corp. (SRBCF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 34.77 Thousand CAD | -31.4% |
| 2022 | 4.2 Million CAD | 64.12% |
| 2021 | 2.56 Million CAD | -40.01% |
| 2020 | 4.27 Million CAD | -7.15% |
| 2019 | 4.6 Million CAD | 107.13% |
| 2018 | 2.22 Million CAD | -10.9% |
| 2017 | 2.49 Million CAD | -24.26% |
| 2016 | 3.29 Million CAD | -6.01% |
| 2015 | 3.5 Million CAD | -4.83% |
| 2014 | 3.68 Million CAD | 40.45% |
| 2013 | 2.62 Million CAD | -13.18% |
| 2012 | 3.02 Million CAD | 37.27% |
| 2011 | 2.2 Million CAD | 105.72% |
| 2010 | 1.06 Million CAD | -12.78% |
| 2009 | 1.22 Million CAD | 838.3% |
| 2008 | 130.7 Thousand CAD | -45.1% |
| 2007 | 238.06 Thousand CAD | 3967850.0% |
| 2006 | -6.00 CAD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 542.64 Thousand CAD | -30.37% |
| 2024 Q1 | 779.28 Thousand CAD | 45.03% |
| 2024 Q3 | 668.47 Thousand CAD | -99.53% |
| 2023 Q2 | 818.44 Thousand CAD | 31.59% |
| 2023 FY | 2.88 Million CAD | -31.4% |
| 2023 Q1 | 621.98 Thousand CAD | 62.93% |
| 2023 Q4 | 537.32 Thousand CAD | 16.72% |
| 2023 Q3 | 460.35 Thousand CAD | -43.75% |
| 2022 Q4 | 381.74 Thousand CAD | -63.17% |
| 2022 Q3 | 1.03 Million CAD | 36.51% |
| 2022 FY | 4.2 Million CAD | 64.12% |
| 2022 Q1 | 2.03 Million CAD | 429.02% |
| 2022 Q2 | 759.29 Thousand CAD | -62.63% |
| 2021 Q1 | 688.69 Thousand CAD | 29.03% |
| 2021 FY | 2.56 Million CAD | -40.01% |
| 2021 Q2 | 971.3 Thousand CAD | 41.04% |
| 2021 Q4 | 384.05 Thousand CAD | -74.26% |
| 2021 Q3 | 1.49 Million CAD | 53.62% |
| 2020 Q3 | 627.58 Thousand CAD | -1.31% |
| 2020 Q4 | 533.72 Thousand CAD | -14.95% |
| 2020 Q2 | 635.94 Thousand CAD | -74.35% |
| 2020 Q1 | 2.47 Million CAD | 81.85% |
| 2020 FY | 4.27 Million CAD | -7.15% |
| 2019 Q2 | 1.28 Million CAD | 112.93% |
| 2019 Q3 | 1.35 Million CAD | 5.05% |
| 2019 FY | 4.6 Million CAD | 107.13% |
| 2019 Q4 | 1.36 Million CAD | 0.88% |
| 2019 Q1 | 604.13 Thousand CAD | 10.02% |
| 2018 FY | 2.22 Million CAD | -10.9% |
| 2018 Q4 | 549.11 Thousand CAD | 19.14% |
| 2018 Q1 | 631.35 Thousand CAD | -3.71% |
| 2018 Q2 | 581.82 Thousand CAD | -7.85% |
| 2018 Q3 | 460.9 Thousand CAD | -20.78% |
| 2017 FY | 2.49 Million CAD | -24.26% |
| 2017 Q3 | 601.4 Thousand CAD | -13.27% |
| 2017 Q2 | 693.4 Thousand CAD | 27.28% |
| 2017 Q1 | 544.77 Thousand CAD | -34.63% |
| 2017 Q4 | 655.7 Thousand CAD | 9.03% |
| 2016 Q2 | 780.97 Thousand CAD | 1.11% |
| 2016 Q4 | 833.37 Thousand CAD | -8.19% |
| 2016 Q3 | 907.7 Thousand CAD | 16.23% |
| 2016 FY | 3.29 Million CAD | -6.01% |
| 2016 Q1 | 772.37 Thousand CAD | 57.29% |
| 2015 FY | 3.5 Million CAD | -4.83% |
| 2015 Q1 | 1 Million CAD | 141.83% |
| 2015 Q4 | 491.04 Thousand CAD | -56.35% |
| 2015 Q3 | 1.12 Million CAD | 29.41% |
| 2015 Q2 | 869.29 Thousand CAD | -13.2% |
| 2014 FY | 3.68 Million CAD | 40.45% |
| 2014 Q4 | 414.1 Thousand CAD | -40.32% |
| 2014 Q3 | 693.81 Thousand CAD | -54.76% |
| 2014 Q2 | 1.53 Million CAD | 47.25% |
| 2014 Q1 | 1.04 Million CAD | 73.25% |
| 2013 Q4 | 601.17 Thousand CAD | -1.4% |
| 2013 FY | 2.62 Million CAD | -13.18% |
| 2013 Q2 | 723.83 Thousand CAD | 5.25% |
| 2013 Q1 | 687.7 Thousand CAD | -35.19% |
| 2013 Q3 | 609.68 Thousand CAD | -15.77% |
| 2012 Q3 | 580.87 Thousand CAD | -25.42% |
| 2012 Q2 | 778.91 Thousand CAD | 26.44% |
| 2012 FY | 3.02 Million CAD | 37.27% |
| 2012 Q1 | 616.01 Thousand CAD | -19.27% |
| 2012 Q4 | 1.06 Million CAD | 82.68% |
| 2011 Q2 | 506.82 Thousand CAD | 9.97% |
| 2011 Q3 | 491.38 Thousand CAD | -3.05% |
| 2011 Q1 | 460.86 Thousand CAD | -3.43% |
| 2011 FY | 2.2 Million CAD | 105.72% |
| 2011 Q4 | 763.02 Thousand CAD | 55.28% |
| 2010 Q1 | 202.62 Thousand CAD | -28.2% |
| 2010 Q4 | 477.22 Thousand CAD | 127.36% |
| 2010 Q2 | 179.52 Thousand CAD | -11.4% |
| 2010 Q3 | 209.9 Thousand CAD | 16.92% |
| 2010 FY | 1.06 Million CAD | -12.78% |
| 2009 Q2 | 667.09 Thousand CAD | 783.82% |
| 2009 Q3 | 201.63 Thousand CAD | -69.77% |
| 2009 FY | 1.22 Million CAD | 838.3% |
| 2009 Q4 | 282.2 Thousand CAD | 39.96% |
| 2009 Q1 | 75.47 Thousand CAD | 110.64% |
| 2008 Q4 | 35.83 Thousand CAD | 57.98% |
| 2008 Q3 | 22.68 Thousand CAD | -52.29% |
| 2008 FY | 130.7 Thousand CAD | -45.1% |
| 2008 Q1 | 24.75 Thousand CAD | -18.15% |
| 2008 Q2 | 47.54 Thousand CAD | 92.03% |
| 2007 FY | 238.06 Thousand CAD | 3967850.0% |
| 2007 Q3 | 23.32 Thousand CAD | -39.87% |
| 2007 Q1 | 145.69 Thousand CAD | 0.0% |
| 2007 Q4 | 30.24 Thousand CAD | 29.66% |
| 2007 Q2 | 38.79 Thousand CAD | -73.37% |
| 2006 FY | -6.00 CAD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 99.96% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 99.293% |
| SQZ Biotechnologies Company | 85.61 Million USD | 99.959% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 99.882% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 99.907% |
| Mesoblast Limited | 5.9 Million USD | 99.411% |
| Propanc Biopharma, Inc. | 1.5 Million USD | 97.684% |
| Genus plc | 147.7 Million USD | 99.976% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 99.604% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | 97.408% |
| Marizyme, Inc. | 19.23 Million USD | 99.819% |
| ContraFect Corporation | 56.88 Million USD | 99.939% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 99.583% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 99.211% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | 97.648% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 98.807% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 98.754% |
| MultiCell Technologies, Inc. | 567.42 USD | -6029.322% |
| Accustem Sciences Inc. | 3.74 Million USD | 99.072% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 99.96% |
| EV Biologics, Inc. | 531.96 Thousand USD | 93.462% |
| Q BioMed Inc. | 3.43 Million USD | 98.988% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 99.859% |
| Neon Bloom, Inc. | 389.56 Thousand USD | 91.072% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 98.676% |
| Biomind Labs Inc. | 994.18 Thousand USD | 96.502% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 225.49 Million USD | 99.985% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 99.482% |
| Skye Bioscience, Inc. | 13.54 Million USD | 99.743% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 98.302% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 239.116% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 99.31% |
| IMV Inc. | 37.7 Million USD | 99.908% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 99.783% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 98.105% |
| GB Sciences, Inc. | 1.42 Million USD | 97.552% |
| Alpha Cognition Inc. | 9.7 Million USD | 99.642% |
| HST Global, Inc. | 140.9 Thousand USD | 75.318% |
| CSL Limited | 3.44 Billion USD | 99.999% |
| Halberd Corporation | 74.84 Thousand USD | 53.53% |
| Enzolytics Inc. | 2.17 Million USD | 98.404% |
| Resverlogix Corp. | 12.71 Million USD | 99.726% |
| Affymax, Inc. | 39.38 Million USD | 99.912% |
| SYBLEU INC | 160.87 Thousand USD | 78.381% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 99.047% |
| argenx SE | 1.53 Billion USD | 99.998% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 99.939% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | 96.669% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 97.798% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 98.979% |
| AVAX Technologies, Inc. | 7.31 Million USD | 99.524% |
| Zenith Capital Corp. | 8.94 Million USD | 99.611% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.996% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -99.638% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 98.584% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | 79.722% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 99.965% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 98.024% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 1.97 Million USD | 98.236% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 98.135% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 99.68% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 98.189% |
| BioStem Technologies, Inc. | 22.97 Million USD | 99.849% |
| ONE Bio Corp. | 6.44 Million USD | 99.46% |
| Reve Technologies, Inc. | 181.48 Thousand USD | 80.836% |
| Burzynski Research Institute, Inc. | 1.33 Million USD | 97.396% |
| Wesana Health Holdings Inc. | 1.12 Million USD | 96.908% |
| Agentix Corp. | 1.37 Million USD | 97.465% |
| LadRx Corporation | 3.81 Million USD | 99.088% |
| Cell Source, Inc. | 4.32 Million USD | 99.196% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | 91.629% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 96.234% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | 96.234% |
| NovAccess Global Inc. | 2.46 Million USD | 98.59% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 98.554% |
| Itoco Inc. | 919.14 Thousand USD | 96.216% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 99.179% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | 96.892% |
| Kadimastem Ltd | 2.41 Million USD | 98.557% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | 86.712% |
| CytoDyn Inc. | 18.05 Million USD | 99.807% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -38.182% |
| Mobile Lads Corp. | 554.54 Thousand USD | 93.728% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | 84.197% |
| Qrons Inc. | 643.67 Thousand USD | 94.597% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | 97.55% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 2.22 Million USD | 98.44% |
| Rebus Holdings, Inc. | 664 Thousand USD | 94.762% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 98.085% |
| International Stem Cell Corporation | 5.27 Million USD | 99.34% |
| Bioxytran, Inc. | 3.82 Million USD | 99.09% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | 33.933% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -70.963% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 99.904% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 97.85% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | 95.274% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 98.882% |
| Neutra Corp. | 243.82 Thousand USD | 85.736% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 99.801% |
| PureTech Health plc | 144.59 Million USD | 99.976% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 99.83% |
| IXICO plc | 4.7 Million USD | 99.261% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 99.605% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 99.97% |
| CSL Limited | 3.89 Billion USD | 99.999% |
| Cellectis S.A. | 97.32 Million USD | 99.964% |